New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:18 EDTRXIIRXi Pharmaceuticals reports Q1 EPS (32c), one estimate (31c)
Reports Q1 revenue $29K, one estimate $80.00K.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
09:03 EDTRXIIRXi Pharmaceuticals and MirImmune enter into exclusive licensing agreement
RXi Pharmaceuticals and privately-held MirImmune announced that they have entered into an exclusive license agreement to RXi's novel and proprietary sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration has the potential to result in novel, more effective and patient friendly cancer treatments that could be a significant step toward personalized medicine. Under the terms of the agreement, MirImmune will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. It will develop cell-based therapeutics utilizing RXi's sd-rxRNA technology to target immune inhibitory pathways which are responsible for limiting the efficacy of cancer immunotherapies. According to the terms, MirImmune will gain access to RXi's sd-rxRNA and rxRNAori® patent families for ex vivo modification of cells for the treatment of cancer. These patents include the composition of the sd-rxRNA and rxRNAori RNAi structures, as well as potential targets for cell-based therapeutics. As consideration for this license, RXi will receive an annual licensing fee, clinical milestone payments, sublicensing income and single digit royalties. Pending MirImmune's achievement of a few gating milestones, RXi will have the right to acquire a double-digit equity stake in MirImmune.
March 23, 2015
07:15 EDTRXIIRXi Pharmaceuticals reports positive advancements in dermatology programs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use